Dr. Shan Lu’s laboratory working with Waisman Biomanufacturing and Eurofins completed the stability program for its DNA vaccine manufactured in 2015. The results show vaccine is very stable and can be used in clinical trials.
PDPHV vaccine candidate was developed in the laboratory of Dr. Shan Lu at the University of Massachusetts Medical School (UMMS). In 2015, using the funding provided by NIAID’s IPCAVD program, the laboratory manufactured the DNA vaccine to be used in the HVTN 124 clinical trial. At the time, a 5-year program was launched to monitor the stability of the five-valent vaccine to support its continued use in the clinical trial. The program recently ended, and the data review showed no noticeable degradation of the product.
WHV will use the remaining DNA product in its planned Phase 1 study. In parallel, it will extend the stability study to further monitor the preservation of this DNA vaccine.
